A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 374-379

  Ryan, Christopher W ^a   Vuky, Jacqueline ^b   Chan, Joseph S ^a   Chen, Zunqiu ^c   Beer, Tomasz M ^a   Nauman, Deirdre ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Everolimus; Imatinib; Phase II clinical trial; Renal cell carcinoma

Indexed keywords

EVEROLIMUS; IMATINIB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAPAMYCIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY CARCINOMA; LEUKOPENIA; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; AGED; CANCER STAGING; CLINICAL TRIAL; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79957552225     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9365-y     Document Type: Article

References (19)

1. Kaelin WG Jr (2004) The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S-6295S (Pubitemid 39287480)
2. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281. doi:356/22/2271 [pii] 10.1056/NEJ Moa066838 (Pubitemid 46849157)
4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456. doi:S0140-6736(08)61039-9 [pii] 10.1016/S0140-6736(08)61039-9
5. Ostman A, Heldin CH (2007) PDGF Receptors as Targets in Tumor Treatment. Adv Cancer Res 97:247-274. doi:S0065-230X (06)97011-0 [pii] 10.1016/S0065- 230X(06)97011-0 (Pubitemid 46528991)
6. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A (2003) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120:107-112. doi:10.1309/LQ9EMK8Q- KE75-NGGX (Pubitemid 37046377)
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 (Pubitemid 32267972)
8. Vuky J, Isacson C, Fotoohi M, dela Cruz J, Otero H, Picozzi V, Malpass T, Aboulafia D, Jacobs A (2006) Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 24:85-88. doi:10.1007/s10637-005-4543-z (Pubitemid 43163424)
9. Hainsworth JD, Spigel DR, Sosman JA, Burris HA, 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM and Greco FA (2007) Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/ imatinib: a phase I/II trial. Clin Genitourin Cancer 5:427-432 (Pubitemid 351219695)
10. Polite BN, Desai AA, Manchen B, Stadler WM (2006) Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer 4:275-280 (Pubitemid 43779885)
11. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295. doi:10.1172/JCI17929 (Pubitemid 36554699)
12. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15:1612-1622. doi:1078-0432.CCR-08-2057 [pii] 10.1158/1078-0432.CCR-08-2057
13. van oosterom A, Reichardt P, Blay J-Y, Dumez H, Fletcher J, Debiec-Rychter M, Shand N, Drimitrijevic S, Yap A, Demetri g (2005) A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinalstromal tumor (GIST) refractory to IM: Study update. J Clin Oncol 23:9033
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
16. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10. doi:0197-2456(89)90015-9 [pii] (Pubitemid 19099520)
17. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463 (Pubitemid 41079774)
18. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480. doi:10.1056/NEJMoa020461 347/7/472 [pii] (Pubitemid 34879334)
19. Fuchs U, Zittermann A, Berthold HK, Tenderich G, Deyerling KW, Minami K, Koerfer R (2005) Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 79:981-983. doi:00007890- 200504270-00020 [pii] (Pubitemid 40586875)